منابع مشابه
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an approved reference biologic product. Given their complexity, biosimilars require attention and a con...
متن کاملBiosimilar medical products - licensing, pharmacovigilance and interchangeability.
The use of biological medicine has significantly increased in recent decades and has made substantial contributions to improving the effectiveness of therapies in many diseases. The expiration of patents of biological innovative medicines enables copies of those drugs called similar biological products (biosimilars) to be approved by regulatory authorities and to enter in clinical use. Biosimil...
متن کاملPharmacovigilance in epileptic patients using antiepileptic drugs.
OBJECTIVE To investigate the occurrence of adverse effects of antiepileptic drugs (AED) in chronic epileptic patients in mono or polytherapy. METHOD We evaluated consecutive patients that met the following inclusion criteria: age of 18 years or older, diagnosis of epilepsy for at least one year, stable dose of AED for at least three months. Patients were asked if they had any adverse event re...
متن کاملNeed of Pharmacovigilance in AYUSH Drugs
In India, Ayurveda, Siddha and Unani (ASU) systems of medicine are considered to be the oldest system of medicines. They prescribe drugs of herbal, mineral, metallic and animal origin for the treatment of many diseases. Being time tested systems of medicine and majority of the drugs used by them are of herbal origin these systems are considered to be safe. The use of ASU medicines continues to ...
متن کاملRegulatory and clinical considerations for biosimilar oncology drugs.
Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological drugs-provide opportunities both to improve health-care access and outcomes, and to reduce costs...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmaceutica Analytica Acta
سال: 2015
ISSN: 2153-2435
DOI: 10.4172/2153-2435.1000416